GeneDx announced a commercial push into the general pediatrics market, hiring sales teams and streamlining ordering to capture demand after the American Academy of Pediatrics recommended exome/genome sequencing as first‑tier tests for developmental delay and intellectual disability. The strategy coincides with strong Q3 financials: GeneDx reported a 52% year‑over‑year revenue rise driven by exome and genome testing growth and raised full‑year guidance. Management emphasized a market‑driven rollout, aligning sales deployments with patient density and reimbursement conditions. The move signals accelerating penetration of comprehensive genomic testing into mainstream pediatric care and highlights how guideline shifts can create rapid commercial opportunities for diagnostics firms with scalable NGS capabilities.